Gilead Sciences and Vir Biotechnology have significantly expanded their strategic research and development alliance through a newly finalized licensing agreement…
Read More
Novartis Secures Strategic Partnership with Abogen to Advance Novel T-Cell Engager Therapies in Autoimmune Disease
The landscape of pharmaceutical partnerships continues to evolve at a rapid pace, marked by strategic alliances designed to tackle complex…
Read More
GSK Expands Oncology Footprint with Chimagen Trispecific T-Cell Engager Deal for Multiple Myeloma
British pharmaceutical giant GSK has significantly deepened its footprint in the oncology sector by securing the global rights to an…
Read More
Voro Therapeutics and Alloy Therapeutics Forge Strategic Partnership to Revolutionize Tumour-Selective T-Cell Engager Therapies
Voro Therapeutics and Alloy Therapeutics have announced a significant strategic research partnership aimed at developing a new generation of masked…
Read More
Bristol Myers Squibb and Oxford BioTherapeutics Forge Alliance to Pioneer Novel T-Cell Engager Therapies for Solid Tumors
Bristol Myers Squibb (BMS) and Oxford BioTherapeutics (OBT) have announced a significant strategic alliance aimed at discovering and developing a…
Read More
Excalipoint Therapeutics Launches with $68.7 Million Seed Funding to Advance Novel T-Cell Engager Pipeline
Chinese biotech startup Excalipoint Therapeutics has officially launched with a substantial $68.7 million in seed funding, positioning itself to accelerate…
Read More
